EVOKE PHARMA, INC. (NASDAQ:EVOK) Files An 8-K Entry into a Material Definitive Agreement
Item 1.01Entry into a Material Definitive Agreement.
On December 15, 2016, Evoke Pharma, Inc. (the Company) entered
into amendments (the Warrant Amendments) with certain of the
holders (the Holders) of the Companys outstanding warrants to
purchase common stock issued on July 25, 2016 and August 3, 2016.
to the Warrant Amendments, the Holders right to require the
Company to purchase the outstanding warrants upon the occurrence
of certain fundamental transactions will not apply if the
fundamental transaction is a result of a transaction that has not
been approved by the Companys board of directors.
The foregoing summary of the Warrant Amendments is subject to,
and qualified in its entirety by reference to, the form of
Warrant Amendment, which is attached hereto as Exhibit 4.1, and
is incorporated herein by reference.
Item 9.01Financial Statements and Exhibits
|
Exhibit Number |
Exhibits |
|
4.1 |
Form of Warrant Amendment, dated December 15, 2016 |
About EVOKE PHARMA, INC. (NASDAQ:EVOK)
Evoke Pharma, Inc. is a specialty pharmaceutical company. The Company is focused primarily on the development of drugs to treat gastrointestinal (GI) disorders and diseases. The Company is developing EVK-001, a metoclopramide nasal spray for the relief of symptoms associated with acute and recurrent diabetic gastroparesis in women. EVK-001 is a formulation of Metoclopramide drug, designed to provide systemic delivery of metoclopramide through intranasal administration. The Company has evaluated EVK-001 in a multicenter, randomized, double-blind, placebo-controlled parallel group, dose-ranging Phase IIb clinical trial. The Company has commenced a Phase III clinical trial of EVK-001 in female patients with symptoms associated with acute and recurrent diabetic gastroparesis. The Phase III clinical trial is a multicenter, randomized, double-blind, placebo-controlled, parallel-group study evaluating the efficacy, safety and population pharmacokinetics of EVK-001 in adult females. EVOKE PHARMA, INC. (NASDAQ:EVOK) Recent Trading Information
EVOKE PHARMA, INC. (NASDAQ:EVOK) closed its last trading session down -0.09 at 1.98 with 3,072,409 shares trading hands.
